Analyst Price Target is $10.00
▲ +966.10% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Enveric Biosciences in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 966.10% upside from the last price of $0.94.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Enveric Biosciences. This Buy consensus rating has held steady for over two years.
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Read More